Sesame / Success by Sesame Review: What Its GLP-1 Documentation Establishes

01Start with what Sesame is selling

Success by Sesame is a care-access subscription, not an all-inclusive medication package. Sesame, Inc., also identified as Sesame or SesameCare, operates through its website and mobile applications. Its homepage says affiliated practices are independently owned and operated by licensed clinicians using the platform. That separation matters: platform enrollment, clinical judgment and medication dispensing are different responsibilities, even when the experience begins on a single website.

The advertised subscription includes telehealth visits, unlimited messaging and ongoing clinical care from a selected provider. Follow-up features include video care, provider messages, weight tracking and tools addressing sleep, exercise and eating habits. These are documented service components, not evidence that a particular patient will receive a particular prescription or achieve a specified result. Sesame’s terms expressly leave prescribing to the provider’s discretion and medical necessity, without guaranteeing a prescription.

The available material is therefore strongest as evidence of an intended service model. It is weaker as evidence of operational performance: it does not establish message-response times, a mandatory follow-up schedule or independently measured treatment outcomes. Our guide to what public provider documents can prove explains that distinction. A detailed service description can help someone prepare for enrollment without proving how consistently the service performs in practice.

02What happens between the questionnaire and a prescription

The documented entry process starts with a brief questionnaire about weight-loss goals and program personalization, followed by provider selection. A video consultation then covers medical history and goals. The provider can order laboratory testing when metabolic information is needed and develop a treatment plan. These steps establish a clinical decision point rather than automatic fulfillment of a customer’s preferred drug request; neither completing the questionnaire nor paying the subscription guarantees medication.

Access also has geographic and age boundaries. The general terms require users to be at least 18, or the local age of majority if higher, and located in a state where the service is offered. During a consultation, the patient must be in the same state as the shipping address recorded in the account. The consulted documentation does not supply a complete program-availability list or confirm which clinicians and medications are available in each location.

Sesame describes ideal medication candidates using BMI thresholds of at least 30, or at least 27 with weight-related conditions. NIDDK describes similar general thresholds, but emphasizes that medication selection also involves health conditions, other medicines, side effects, family history and cost. These thresholds are not an individualized eligibility determination. Sesame’s page also says GLP-1 medications should be avoided by people with a history of pancreatitis, a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2) or type 1 diabetes. These are the provider’s stated restrictions; individual suitability requires clinical assessment. Sesame also states that its providers do not prescribe controlled weight-loss medications, an important boundary for anyone expecting access to every weight-management option.

03The medication menu is not a single evidence claim

Sesame’s pages describe several products and presentations, making exact identification important. Its Wegovy page presents semaglutide as both a weekly injection and a daily oral tablet. Its Zepbound page describes single-dose pens, multidose KwikPens containing a month’s supply, and single-dose glass vials requiring a separate needle and syringe. Those are provider descriptions of offerings; the evidence reviewed here does not independently verify their regulatory status or real-time availability.

The program also presents Foundayo, identified as orforglipron, as a daily oral GLP-1 option and makes a product-specific FDA-approval claim. That claim is not independently established by this review’s regulatory material. Separately, Sesame lists Ozempic, Mounjaro, Rybelsus, Victoza and metformin as diabetes medications that may cause weight loss. Their appearance together does not make them interchangeable, establish the same indication for each, or mean every listed medicine belongs to the same drug class.

FDA approval concerns a specific product, not Sesame as a platform. Likewise, evidence about one formulation cannot simply be assigned to another route or preparation. The guide to formulation and route differences develops that issue. If a compounded preparation is discussed during care, FDA says such preparations are not FDA approved and recommends them when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not establish clinical inequivalence.

04Clinical studies do not measure Success by Sesame

STEP 1 studied 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Over 68 weeks, mean weight change was −14.9% with subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo; both groups received lifestyle intervention. Gastrointestinal events led to discontinuation in 4.5% and 0.8%, respectively. Novo Nordisk funded the trial. The dose identifies the study arm, not instructions for readers, and the results do not measure Sesame’s care.

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes. At 72 weeks, mean changes were −15.0%, −19.5% and −20.9% with studied weekly subcutaneous tirzepatide doses of 5, 10 and 15 mg, respectively, versus −3.1% with placebo. Gastrointestinal adverse events were most common. Adverse-event discontinuation rates were 4.3%, 7.1% and 6.2% in those treatment groups, versus 2.6% with placebo. Eli Lilly funded the study.

These trials support specific treatment evidence under defined conditions, not a ranking of telehealth companies. They are not a head-to-head comparison and do not establish results for Sesame patients, oral versions, compounded preparations or an individual. The consulted Sesame material does not provide a provider-specific outcomes study for comparison. As explained in why a trial is not a company performance report, access to a researched medicine and measured success delivering care are separate propositions.

05Subscription prices need to be read alongside the billing clock

The headline starting price is $59 per month with an annual subscription, excluding medication. Sesame says annual subscriptions are billed once every 12 months in advance; six- and three-month plans are also billed in advance at their respective intervals. The flexible plan is advertised at $99 per month, but a separate explanation says every 28 days. Four weeks is not a calendar month, so the renewal date requires confirmation rather than assumption.

Sesame advertises savings against its monthly plan of $480 per year for annual enrollment, $180 every six months and $60 every three months. Those are the provider’s comparisons, not independently calculated savings here. Providers set their own prices and may charge more than the advertised starting rate. The useful checkout question is therefore the actual amount collected, the selected term and its renewal interval—not merely whether a page displays a monthly equivalent.

Laboratory inclusion has a similarly specific boundary. The subscription covers work completed at Quest Diagnostics facilities except those in Arizona, Hawaii, North Dakota, New Jersey, New York, Oklahoma, Rhode Island, South Dakota and Wyoming. Testing fees in those states are additional. The documentation does not establish a universal alternative-laboratory benefit. Together with separate medication charges, this means the subscription headline is not a complete estimate of an individual’s treatment expenses.

06Drug prices depend on presentation, channel and eligibility

Sesame publishes concrete cash-price examples, summarized below, but none includes the Success subscription. Its Wegovy page directs patients to have prescriptions sent to NovoCare for reduced cash pricing. The Zepbound examples are specifically through LillyDirect. These channel restrictions matter: a displayed manufacturer-linked price should not be assumed to apply at every local pharmacy or through every delivery arrangement. Prices here describe the consulted pages, not independently confirmed transactions.

The $199 injection promotion applies to new U.S. self-pay Wegovy or Ozempic patients whose prescriber authorizes treatment, for the first two consecutive months at the specified 0.25 mg or 0.5 mg presentations. Its stated window is November 17, 2025, through December 31, 2026. People enrolled in federal or state healthcare programs with prescription coverage are excluded. The Wegovy card advertises $349 monthly afterward; promotional medication pricing does not discount subscription or service fees.

There is also a small but concrete Zepbound discrepancy. The dedicated page lists KwikPens at $399 for 5 mg and $699 for 10, 12.5 and 15 mg; the main program page instead displays $398 and $698. The dedicated page’s other KwikPen figures are $299 for 2.5 mg and $499 for 7.5 mg. These are presentation-specific price listings, not dosing recommendations. Written pharmacy confirmation is more useful than choosing whichever page shows the lower figure.

07Insurance, refills and delivery cross organizational boundaries

Sesame says it does not bill health insurance for the program, although insurance may cover a prescribed drug. It also says the provider will handle prior-authorization paperwork with the insurer. That is administrative assistance, not a coverage guarantee. More consequentially, the telemedicine terms require users to certify that they are not federal healthcare-program beneficiaries, naming Medicare, Medicaid and TRICARE as examples. That restriction needs reconciliation with broad marketing about access regardless of insurance.

For prescriptions, the program advertises same-day pickup at a preferred local pharmacy or home delivery. Its terms identify Truepill as a pharmacy partner while emphasizing that Sesame itself is not a pharmacy. The Wegovy page describes requesting refills by messaging the provider rather than booking a dedicated refill visit. This documents a request pathway, not guaranteed authorization, immediate response or pharmacy inventory. No specific messaging turnaround or mandatory follow-up frequency is established in the reviewed material.

The delivery description leaves shipping charges, carriers, arrival estimates, refrigeration procedures and loss-or-damage policies unresolved. Same-day pickup language is not a promise of same-day home arrival. FDA explicitly advises not using an injectable GLP-1 product that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. Our guide to reading delivery claims carefully separates prescription, dispatch and arrival claims—steps that should not be collapsed into one promise.

08Cancellation is the clearest unresolved documentary conflict

The program page offers a full refund when enrollment is canceled at least three hours before the initial visit starts. Once that visit occurs, it says the first month is nonrefundable. It also describes self-cancellation at any point, requiring cancellation before the next billing cycle to avoid further charges and excluding refunds for previous months. Those statements distinguish stopping future billing from recovering money already paid; they should not be read as an unconditional refund promise.

General membership terms use a different procedure: cancel by emailing support@sesamecare.com or calling +1 (877) 947-6411 at least 48 hours before the applicable renewal processing date. They allow continued access through the paid monthly or annual term but exclude prorated refunds. The reviewed documentation does not settle which instruction controls a specific Success enrollment or how all prepaid three-, six- and twelve-month situations are handled. Confirming both the deadline and method before enrollment would resolve a material uncertainty.

Support also has a documented financial-administration role: Sesame says users can request an itemized bill at support@sesamecare.com for possible HSA or FSA reimbursement. It describes most subscription services as potentially eligible, not universally reimbursable. The reviewed material does not establish support hours or language assistance. Moreover, the available terms text omits an intermediate section, limiting any claim that this review captures every contractual condition. These are reasons to obtain written answers, not proof of undisclosed misconduct.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Sesame / Success by Sesame — official website ↗
6. Sesame / Success by Sesame — terms of service ↗
7. Sesame / Success by Sesame — medication/zepbound ↗
8. Sesame / Success by Sesame — medication/wegovy ↗
9. Sesame / Success by Sesame — service/online weight loss program ↗

Continue reading

• What Public GLP-1 Provider Documents Can—and Cannot—Prove
• A Clinical Trial Is Not a Telehealth Company Performance Report
• Same Ingredient Name, Different Evidence Questions
• Reading GLP-1 Cold-Chain and Delivery Claims Carefully
• Follow-up Is a Clinical Question, Not Just a Renewal Notice